Abstract. Adrenocortical carcinoma (ACC) is an invasive tumor that occurs in the endocrine system. Increasing evidence has shown that endoplasmic reticulum (ER) stress and autophagy play an important role in tumor formation. Tauroursodeoxycholic acid (TUDCA) is an ER chemical chaperone that can alleviate ER stress. In the present study, TUDCA promoted the proliferation, migration and invasion of ACC SW-13 and NCI-H295R cells. Reverse transcription-quantitative PCR and western blot analysis showed that the expression of glucose-regulated protein 78, a promoter of ER stress, was decreased. The expression levels of protein kinase R (PKR)-like ER kinase and activating transcription factor 6 were correspondingly decreased, and the downstream proteins, C/EBP homologous protein and JNK, were also decreased. The expression levels of the autophagy factor microtubule-associated protein light chain 3-II/I and the anti-apoptotic factor Bcl-2 increased following TUDCA treatment, while the expression of the pro-apoptotic factor Bax decreased. TUDCA alleviated ER stress in ACC SW-13 and NCI-H295R cells and induced autophagy, thereby inhibiting ACC cell apoptosis. ER stress- and autophagy-related signaling pathways are involved in the occurrence of ACC, which may provide potential therapeutic targets for ACC treatment.

Introduction

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy, with an incidence rate of 1.5 to 2 cases per million people per year worldwide (1). Albeit rare, ACC is often aggressive and lethal, with 10-20% of patients surviving 5 years after diagnosis (2). To date, the main curative therapy for ACC is surgical resection of the primary tumor. However, most patients with an advanced stage of the disease have a median survival time of <12 months, even after complete tumor resection (3). Even with ostensibly complete resections, the rates of local recurrence have typically ranged from at least 19 to 34% in those patients with no residual disease after surgery (4,5). Mitotane remains the only drug approved for ACC treatment by the U.S. Food and Drug Administration and European Medicine Executive Agency (6). However, mitotane is an adjuvant therapy for patients with low to moderate risk for ACC recurrence, and its efficacy is ultimately limited by its high lipophilicity, poor pharmacokinetic properties, and dose-limiting toxicities (7). In addition, long-term radiotherapy may be used in patients at an increased risk of local recurrence (8). The high degree of malignancy, strong invasiveness, poor traditional treatment efficacy and poor prognosis of ACC have led to the exploration of targeted therapy.

A recent study has demonstrated that endoplasmic reticulum (ER) stress may play an important role in the development of cancer (9). Alterations in the homeostasis and appropriate functioning of the ER initiates a cascade of signaling events known as the ER stress response or unfolded protein response (UPR). When ER stress occurs, cancer cells in colorectal, breast and cervical cancer, adapt the UPR to alleviate the ER stress condition as a survival approach for progression (10,11). Adaptation of cancer cells to adverse conditions largely relies on the ability of a cell to perturb ER stress-associated regulatory networks and prevent ER stress-induced cell death (12,13). Autophagy is a highly conserved system that delivers misfolded proteins and damaged organelles to the lysosome for degradation, maintaining cell homeostasis (14). Li et al (15) showed
that the ER stress-responsive protein kinase R-like ER kinase (PERK)-eukaryotic initiation factor-2α (eIF2α)-activating transcription factor (ATF) 4 pathway contributes to ER stress-induced autophagy. Persistent ER stress often results in the stimulation of autophagic activities (16).

Tauroursodeoxycholic acid (TUDCA) is a chemical chaperone that stabilizes protein conformation and improves the folding capacity of the ER (17). Yang et al (18) showed that TUDCA could downregulate ER stress in a dose-dependent manner using human hepatocellular carcinoma cells. Guo et al (19) found that TUDCA reversed abnormal autophagy and reduced ER stress in the liver of obese mice. Therefore, TUDCA is a promising regulator for mediating ER stress, which significantly relieves ER stress and inhibits cell apoptosis in the aforementioned cells.

The present study aimed to identify whether ER stress and autophagy are involved in the occurrence of ACC by TUDCA interventions, providing a theoretical basis for the treatment of ACC.

Materials and methods

Cell culture. The SW-13 cell line was obtained from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (cat. no. TCHu221). The NCI-H295R cell line was obtained from the American Type Culture Collection (cat. no. ATCC® CRL-2128). Cells were grown in minimum essential medium supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C and 5% CO2. The SW-13 cell line was cultured in serum-free minimal essential medium supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C for 24 h. When the cells were cultured in serum-free medium for 24 h at 37˚C, then, the upper chambers were precoated with Matrigel matrix (Corning, Inc.), and cells were added to the upper chambers at a concentration of 1x10⁶ cells per well. Next, 500 µl serum-containing medium was added to the lower chambers. After 24 h of incubation, the cells on the upper side of the filters were removed with a cotton swab, and the filters were washed with PBS. The cells were fixed in methanol for 30 min at room temperature, and nuclei were stained with 0.1% crystal violet for 15 min at room temperature. Images were captured under a light microscope, and cell counts were measured using ImageJ software version 1.8.0 (National Institutes of Health).

Reverse transcription-quantitative PCR (RT-qPCR) analysis. Total RNA was extracted from SW-13 cells cultured in different concentrations of TUDCA (0, 100, 200, 300, or 400 µM for 48 h) using RNeasy Plus reagent (Takara Biotechnology Co., Ltd.). Following RNA extraction, cDNA was synthesized using a Takara RT kit (Takara Biotechnology Co., Ltd.) at 37˚C for 15 min, 85˚C for 5 sec and kept at 4˚C until further experimentation. qPCR amplification was conducted with SYBR-Green reagent (Takara Biotechnology Co., Ltd.) using an ABI 7500 sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc.) and the following conditions were used: Initial denaturation at 95˚C for 30 sec, then 40 cycles of 95˚C for 5 sec and 60˚C for 34 sec. The experimental steps were carried out according to the manufacturer's instructions. The primers were designed and synthesized by Sangon Biotech Co., Ltd. (Table I). Cq values were generated using the default analysis settings. ∆Cq was calculated using the following formula: ∆Cq = Cq (gene of interest) - Cq (GAPDH). ∆ΔCq was calculated using the following formula: (ΔCq (treated sample) - Cq (control sample)). Relative expression was calculated using the 2^{-ΔΔCq} method as previously described (20).

Western blot analysis. SW-13 cells were treated with aforementioned concentrations of TUDCA. After 48 h, SW-13 cells were lysed with RIPA lysis buffer containing 1 mM PMSF (Beijing Solarbio Science and Technology Co., Ltd.) for 30 min and then the cells were centrifuged at 14,000 x g for 10 min at 4˚C, and the supernatant was collected. Subsequently, the protein concentration was determined using a BCA protein analysis kit (Beyotime Institute of Biotechnology). A total of 50 µg of total protein was separated using 10% SDS-PAGE and transferred to PVDF membranes (Sigma-Aldrich; Merck KGaA). The membranes were blocked using 5% skimmed milk at room temperature for 1 h and then incubated with primary antibodies at 4˚C overnight. Next, the membranes were washed three times with TBS-Tween 20 and incubated with secondary horseradish peroxidase-conjugated antibody (dilution 1:10,000; cat. no. L3012-2; Signalway Antibody LLC) for 1 h at room temperature. The protein bands were imaged using a densitometric scanner (Bio-Rad Laboratories, Inc.) and analyzed with ImageJ software version 1.8.0 (National Institutes of Health). Antibodies against PERK (dilution 1:1,000; cat. no. 3192),
Table I. Primer sequence for reverse transcription-quantitative PCR.

| Gene name | Primer sequence (5'-3') |
|-----------|------------------------|
| GAPDH     | F: CAGGAGCCATTGCTGATGAT R: GAAGGCTGGGCTCATTT |
| GRP78     | F: CAGGGTTACTGACGCCCTA R: CATTAGGCCAGCAATGTTCC |
| PERK      | F: CCAGTTTTGTACTCAAATGCA R: CAGTACAAGCTGGCTCTATAC |
| CHOP      | F: GAGAATGAAAGGGAAATGGGCAC R: ATTACACATTGGTCATCAACGA |
| JNK       | F: ACACCAAGAATCCTGGAAG R: CACAGCATCTGATAGAGAAGT |
| ATF6      | F: CTGATGCGTTCTCATAACAG R: GATCCCCTGAAAATGACACAAC |
| LC3-II/I  | F: AGGCCCTTTTCTTATCAATAACATC R: AAGATCCTAGCCTGTGCCATTAC |
| Bax       | F: CGAACCTGGAATCAGTAAACGGG R: CAGTNTTCGTCGCAAAGTTAGAAA |
| Bcl-2     | F: GACCTTCCGAGAGTCACAG R: GAACTCAAAGAAGGCCACAATC |

F, forward; R, reverse; GRP78, glucose-regulated protein 78; PERK, protein kinase R-like ER kinase; CHOP, C/EBP homologous protein; ATF6, activating transcription factor 6; LC3, microtubule-associated protein light chain 3.

Results

TUDCA promotes the proliferation, migration, and invasiveness of ACC cells. The effects of TUDCA on SW-13 and NCI-H295R cell proliferation, motility, and invasiveness were investigated. The proliferation of SW-13 and NCI-H295R cells after treatment with different concentrations of TUDCA was measured using a CCK8 assay. The CCK8 assay revealed that TUDCA promoted SW-13 and NCI-H295R cell proliferation. TUDCA at a concentration of 400 µM significantly promoted the proliferation of SW-13 cells, while 600 µM TUDCA significantly promoted NCI-H295R cell proliferation (Fig. 1A and B).

Since the migration and invasion of cancer cells are crucial factors responsible for cancer progression (21), the effect of TUDCA on SW-13 and NCI-H295R cell migration and invasion was examined. The wound healing assays revealed that SW-13 and NCI-H295R cells had different migration potentials after 24 h of intervention with different concentrations of TUDCA. The group treated with 400 µM TUDCA induced the highest percentage of SW-13 cell migration, while 600 µM TUDCA induced the highest percentage of NCI-H295R cell migration (Fig. 2A-D). The Transwell assay confirmed that the invasiveness of SW-13 cells was significantly increased in the 400 µM TUDCA group compared with that in the 0 µM TUDCA group, and the invasiveness of NCI-H295R cells was significantly increased in the 600 µM TUDCA group compared with that in the 0 µM TUDCA group (Fig. 3A-D).

TUDCA alleviates the influence of ER stress in SW-13 cells. In the present study, whether TUDCA regulated the ER stress pathway in SW-13 cells was investigated using RT-qPCR and western blot analyses. The mRNA expression of the ER stress promoter GRP78 was significantly decreased in the 400 µM TUDCA group. In accordance with the changes in mRNA expression, western blot analysis showed that the expression of GRP78 protein was also markedly decreased in the 400 µM TUDCA group compared with that in the 0 µM TUDCA group after 48 h. Decreased expression of GRP78 alleviated ER stress in SW-13 cells. In addition, the expression of ER-related factors was downregulated with TUDCA treatment; PERK and ATF6 mRNA and protein expression levels were significantly reduced in the 400 µM TUDCA group compared with those in the 0 µM TUDCA group.

Statistical analysis. All experiments were repeated three times, and the data were analyzed using SPSS version 17.0 software (SPSS, Inc.). Graphical representation of data was prepared with GraphPad Prism version 5.0 software (GraphPad Software, Inc.). The data are expressed as the mean ± standard deviation. Differences in the data among the groups were analyzed using one-way ANOVA combined with Bonferroni’s post hoc test. P<0.05 was considered to indicate a statistically significant difference.

TUDCA induces autophagy and inhibits apoptosis in SW-13 cells. LC3 serves as one of the most important markers of autophagy. When autophagy occurs, the LC3-I cytosolic form is converted to the LC3-II lipid-conjugated membrane-bound form (22). Our results showed that LC3-II/I expression increased in a concentration-dependent manner after TUDCA intervention, and LC3-II/I mRNA and protein expression in the 400 µM TUDCA group was significantly higher compared with that in the 0 µM TUDCA group (Fig. 5A-C). In addition, TUDCA alleviated ER stress and induced autophagy, thereby inhibiting apoptosis. In the 400 µM TUDCA group, the expression of the anti-apoptotic factor Bcl-2 was upregulated, and the mRNA and protein expression of Bcl-2 was significantly higher in the 400 µM TUDCA group compared with that in the 0 µM TUDCA group. However, the mRNA and protein expression of the pro-apoptotic factor Bax exhibited the opposite expression pattern from Bcl-2 (Fig. 6A-C).
TUDCA is a well-known ER chaperone that alleviates ER stress (23). Activation of the UPR signaling pathway following ER stress plays an important role in tumorigenesis (24). UPR activation involves GRP78, PERK, inositol-requiring protein 1α (IRE1α), and ATF6 (25). The competitive binding of GRP78 with the hydrophobic surfaces of misfolded proteins following ER stress releases these transducers to induce UPR signaling. GRP78, the ER promoter, acts as a major regulator of the UPR through directly interacting with the UPR sensors, namely, PERK,
IRE1α, and ATF6 (26). When TUDCA inhibited ER stress, three ER sensors were also inhibited. The dissociation of GRP78 from PERK, IRE1α, and ATF6 leads to their inhibition. Liu et al (27) administered TUDCA to salivary adenoid...
cystic carcinoma cell cultures 3 h before ceramide treatment. Ceramide-induced X-box binding protein 1 mRNA splicing was significantly inhibited by TUDCA pretreatment, and TUDCA alleviated ceramide-induced eIF2α phosphorylation. Marquardt et al. (28) reported that TUDCA ameliorated maladaptive ER stress signaling and reduced the expression of ATF6 and CHOP. In the present study, it was observed that TUDCA alleviates ER stress and promotes ACC cell proliferation. Thus, ER stress-related signaling pathways play a role in ACC.

Autophagy is important for the secretion of diverse proteins involved in intercellular signaling and cancer progression. Autophagic flux can be upregulated in response to stressful stimuli, such as nutritional, metabolic, oxidative, pathogenic, genotoxic, or proteotoxic stress (29). This stimulus-induced autophagy serves a cytoprotective function by helping cells adapt to stress and promoting cell survival (30,31). As one of the most important markers of autophagy, the transition of LC3 from LC3-I to LC3-II mediates key features of autophagy activation by promoting lysis, lipogenesis, and proteolysis (22). Some studies showed that the PERK-eIF2α-ATF4-CHOP pathway contributed to the ER stress-induced activation of autophagy (32,33). A study by B’Chir et al. (32) showed that the LC3-II/LC3-I ratio was increased after knockout of CHOP. CHOP is a downstream indicator of the ER stress signaling pathway and a key participant in apoptosis. CHOP can activate a death program by inducing both the extrinsic and intrinsic apoptotic pathways, decreasing the expression of the anti-apoptotic protein Bcl-2 while increasing the expression of the pro-apoptotic Bax (34). The present study found that TUDCA alleviated ER stress via the PERK-ATF4-CHOP pathway and induced autophagy in ACC SW-13 cells. Meanwhile, CHOP expression was downregulated, which may inhibit ACC cell apoptosis. A previous study has shown that TUDCA inhibited ER stress in pancreatic cancer cells and blocked the pachymic acid-induced apoptosis of pancreatic cancer (35). These results provide evidence demonstrating that TUDCA alleviated ER stress and induced autophagy in ACC cells, thereby inhibiting the apoptosis of ACC cells.

In conclusion, TUDCA induced autophagy of ACC SW-13 cells and inhibited apoptosis of ACC SW-13 cells after alleviating ER stress of ACC SW-13 cells. ER stress- and autophagy-related signaling pathways are involved in the occurrence of ACC, which may provide potential therapeutic targets for ACC treatment. There is a complex interplay between ER stress and autophagy in ACC. Therefore, an ER stress inducer such as thapsigargin will be used in in vitro and in vivo experiments with ACC in future studies.

Acknowledgements
Not applicable.

Funding
This study was supported by the National Natural Science Foundation of China (grant no. 81060220), the Innovation Project of Guangxi Graduate Education (grant no. YCBZ2018037), and the Guangxi Medical and Health Self-financing Project (grant no. Z20180636).
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
XH, DL and ZL designed the study. XH, LW, YK, XL, XD, XHL, LL, HY, ZH, DL and ZL conducted the study and analyzed the data. XH wrote the manuscript, and ZL revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Xie C, Tanachki S, Raygada M, Davis JL, and Del Rivero J: Case report of an adrenocortical carcinoma associated with germline CHEK2 mutation. J Endocr Soc 3: 284-290, 2018.
2. Xiao H, Xu D, Chen P, Zeng G, Wang X and Zhang X: Identification of five genes as a potential biomarker for predicting progression and prognosis in adrenocortical carcinoma. J Cancer 9: 4484-4495, 2018.
3. Li Y, Bian X, Ouyang J, Wei S, He M and Luo Z: Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma. Cancer Manag Res 10: 6949-6959, 2018.
4. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Correia AP, Hammer GD, Korobkin M and Worden FP: Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocrine-Related Cancer 12: 667-680, 2005.
5. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ and Hammer GD: Adrenocortical carcinoma. Endocr Rev 35: 282-326, 2014.
6. Gonzalez RJ, Tamm EP, Ng C, Pan AT, Vassilopoulos Sellin R, Perrier ND, Evans DB and Lee JE: Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery 142: 867-875, 2007.
7. Schneidhage DR, Honegger GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M and Worden FP: Management of patients with adrenal cancer: Recommendations of an international consensus conference. Endocrine-Related Cancer 12: 667-680, 2005.
8. Mohan DR, Lerario AM and Hammer GD: Therapeutic targets for adrenocortical carcinoma in the genomics era. J Endocr Soc 2: 1259-1274, 2018.
9. Baudin E and Doherty T: Endocrine and Tumor Board of Gustave R: Therapeutic targets for adrenocortical carcinoma in the genomics era. J Endocr Soc 2: 1259-1274, 2018.
32. B’Chir W, Chaveroux C, Carraro V, Averous J, Maurin AC, Jousse C, Muranishi Y, Parry L, Fafournoux P and Bruhat A: Dual role for CHOP in the crosstalk between autophagy and apoptosis to determine cell fate in response to amino acid deprivation. Cell Signal 26: 1385-1391, 2014.

33. Lei Y, Wang S, Ren B, Wang J, Chen J, Lu J, Zhan S, Fu Y, Huang L and Tan J: CHOP favors endoplasmic reticulum stress-induced apoptosis in hepatocellular carcinoma cells via inhibition of autophagy. PLoS One 12: e0183680, 2017.

34. Puthalakath H, O’Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, et al: ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129: 1337-1349, 2007.

35. Cheng S, Swanson K, Eliaz I, McClintick JN, Sandusky GE and Sliva D: Pachymic acid inhibits growth and induces apoptosis of pancreatic cancer in vitro and in vivo by targeting ER stress. PLoS One 10: e0122270, 2015.